Faruqi & Faruqi Urges Soleno Therapeutics Investors to Act Before Class Action Deadline Approaches

Investors Urged to Take Action

In a recent announcement, Faruqi & Faruqi, LLP, one of America's prominent securities law firms, has brought attention to an important deadline concerning Soleno Therapeutics, Inc. (NASDAQ: SLNO). Investors who purchased shares during the period between March 26, 2025, and November 4, 2025, are reminded that they have until May 5, 2026, to participate in a federal class action lawsuit against the company.

Key Allegations Against Soleno

The investigation stems from claims that Soleno Therapeutics and its executives have violated federal securities laws. This includes allegations of providing misleading information regarding the safety and efficacy of their drug, DCCR, specifically concerning the treatment of hyperphagia related to Prader-Willi syndrome (PWS). According to sources, critical flaws in the Phase 3 clinical trials may have been concealed, suggesting potential safety risks that were not transparently communicated to investors or the public.

As detailed in a critical report by Scorpion Capital on August 15, 2025, significant concerns were raised about the safety of DCCR, leading to a dramatic fall in the stock price. Prior to the report, shares were trading at over $77, but soon plummeted approximately 12% following the report's release. Following further incidents, including a patient death linked to DCCR, shares fell drastically from $70 to $57 in just a short period.

The third-quarter financial results disclosed on November 4, 2025, only added fuel to the fire, revealing a disruptive impact on DCCR's launch trajectory due to the negative publicity, contributing to a further 27% drop in stock value.

The Class Action Process

Court actions of this nature are designed to provide investors with an avenue to seek restitution for any financial damages incurred due to alleged misconduct. The lead plaintiff in these cases is often selected based on who has the most significant financial interest in the outcome. This plaintiff will manage the litigation on behalf of the entire class of affected investors while complying with court guidelines.

The law firm encourages any individuals with relevant information regarding Soleno's actions—be they investors, whistleblowers, former employees, or stakeholders—to come forward and contact their office. Your involvement can help build a stronger case against the firm.

If you believe you have a valid legal claim, time is of the essence. Interested parties should reach out to Faruqi & Faruqi directly. You may call the firm at 877-247-4292 or 212-983-9330 to discuss your options or visit their website for additional details on the class action.

This potential class action emphasizes the importance of transparency in pharmaceutical development and investor communication, especially in cases where significant health and safety issues are at stake. As the May deadline looms, affected investors are encouraged to take decisive action to protect their interests.